MRSA

MRSA comeback
Biotech

Basilea opts not to take MRSA antibiotic into clinic

Basilea has cited its “stringent risk-return criteria” as a reason for not taking up its option to bring a MRSA antibiotic into clinical development.
James Waldron Feb 18, 2025 4:08am
A 3D rendering of the COVID-19 virus SARS-CoV-2 Most of the virus particles are blue with a bright red one in the center

Infinity Pharma cancer drug stops COVID, MRSA damage in mice

Jul 9, 2024 7:00am
Walmsley

GSK drops celiac disease program acquired in Sitari buyout

Feb 1, 2023 6:40am
MRSA

'Uninterpretable' phase 3 results stymie ContraFect

Dec 20, 2022 1:18pm
MRSA

ContraFect halts phase 3 after antimicrobial fails futility test

Jul 14, 2022 10:35am
Pills

Fighting superbugs with ‘supercharged’ antibiotics

Jan 8, 2018 9:40am